1
|
Bhavana, Kohal R, Kumari P, Das Gupta G, Kumar Verma S. Druggable targets of protein tyrosine phosphatase Family, viz. PTP1B, SHP2, Cdc25, and LMW-PTP: Current scenario on medicinal Attributes, and SAR insights. Bioorg Chem 2024; 144:107121. [PMID: 38237392 DOI: 10.1016/j.bioorg.2024.107121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Revised: 01/02/2024] [Accepted: 01/10/2024] [Indexed: 02/17/2024]
Abstract
Protein tyrosine phosphatases (PTPs) are the class of dephosphorylation enzymes that catalyze the removal of phosphate groups from tyrosine residues on proteins responsible for various cellular processes. Any disbalance in signal pathways mediated by PTPs leads to various disease conditions like diabetes, obesity, cancers, and autoimmune disorders. Amongst the PTP superfamily, PTP1B, SHP2, Cdc25, and LMW-PTP have been prioritized as druggable targets for developing medicinal agents. PTP1B is an intracellular PTP enzyme that downregulates insulin and leptin signaling pathways and is involved in insulin resistance and glucose homeostasis. SHP2 is involved in the RAS-MAPK pathway and T cell immunity. Cdk-cyclin complex activation occurs by Cdc25-PTPs involved in cell cycle regulation. LMW-PTPs are involved in PDGF/PDGFR, Eph/ephrin, and insulin signaling pathways, resulting in certain diseases like diabetes mellitus, obesity, and cancer. The signaling cascades of PTP1B, SHP2, Cdc25, and LMW-PTPs have been described to rationalize their medicinal importance in the pathophysiology of diabetes, obesity, and cancer. Their binding sites have been explored to overcome the hurdles in discovering target selective molecules with optimum potency. Recent developments in the synthetic molecules bearing heterocyclic moieties against these targets have been explored to gain insight into structural features. The elaborated SAR investigation revealed the effect of substituents on the potency and target selectivity, which can be implicated in the further discovery of newer medicinal agents targeting the druggable members of the PTP superfamily.
Collapse
Affiliation(s)
- Bhavana
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, (Punjab), India
| | - Rupali Kohal
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, (Punjab), India
| | - Preety Kumari
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, (Punjab), India
| | - Ghanshyam Das Gupta
- Department of Pharmaceutics, ISF College of Pharmacy, Moga 142 001, (Punjab), India
| | - Sant Kumar Verma
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga 142 001, (Punjab), India.
| |
Collapse
|
2
|
Gharge S, Alegaon SG. Recent Studies of Nitrogen and Sulfur Containing Heterocyclic Analogues as Novel Antidiabetic Agents: A Review. Chem Biodivers 2024; 21:e202301738. [PMID: 38126280 DOI: 10.1002/cbdv.202301738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Revised: 12/16/2023] [Accepted: 12/19/2023] [Indexed: 12/23/2023]
Abstract
The prevalence of diabetes mellitus is on the rise, which demands the identification of novel antidiabetic drugs. There is a need for safer and more effective alternatives because the therapy methods now available to manage diabetes have limits. Due to their diverse pharmacological characteristics, heterocyclic molecules with nitrogen and Sulfur atoms have become intriguing candidates in medicinal chemistry. These substances have a wide variety of structures that can be customized to target different pathways associated with diabetes and can affect important biological targets involved in glucose homeostasis. This review provides a thorough summary of the most recent studies on heterocyclic analogues of nitrogen and Sulfur as prospective antidiabetic agents. This review examines the variety of their structural forms, their methods of action, and assesses the results of preclinical and clinical investigations on their effectiveness and safety. Additionally, further optimization and development of innovative antidiabetic medications are highlighted, as well as the difficulties and prospects for the future in utilizing the therapeutic potential of these analogues. This study seeks to stimulate additional investigation and cooperation between researchers and medicinal chemists, promoting improvements in the creation of efficient and secure antidiabetic medicines to fulfill the needs in the management of diabetes.
Collapse
Affiliation(s)
- S Gharge
- Department of Pharmaceutical Chemistry, KLE College of Pharmacy, KLE Academy of Higher Education and Research, 590 010, Belagavi, Karnataka, India
| | - S G Alegaon
- Department of Pharmaceutical Chemistry, KLE College of Pharmacy, KLE Academy of Higher Education and Research, 590 010, Belagavi, Karnataka, India
| |
Collapse
|
3
|
Ray PK, Shabana K, Salahuddin, Kumar R. Synthetic Strategies of Thiazolidine-2,4-dione Derivatives for the Development of New Anti-diabetic Agents: Compressive Review. Curr Top Med Chem 2024; 24:885-928. [PMID: 38500288 DOI: 10.2174/0115680266284283240304071648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 02/06/2024] [Accepted: 02/13/2024] [Indexed: 03/20/2024]
Abstract
BACKGROUND Thiazolidine-2,4-dione (2,4-TZD) is a flexible pharmacophore and a privileged platform and contains a five-membered ring with a 2-oxygen atom with double bond 2,4- position and one nitrogen atom as well as sulphur containing in the heterocyclic compound. A famous electron-rich nitrogen transporter combines invigorating electronic properties with the prospective for elemental applications. Thiazolidine-2,4-dione analogues have been synthesized using a variety of methods, all of which have shown to have a strong biological effect. OBJECTIVES The study of the biological activity of Thiazolidine-2,4-dione derivatives has been a fascinating field of pharmaceutical chemistry and has many purposes. This derivative described in the literature between 1995 to 2023 was the focus of this study. Thiazolidine-2,4-diones have been discussed in terms of their introduction, general method, synthetic scheme and antidiabetic significance in the current review. CONCLUSION Thiazolidine-2,4-diones are well-known heterocyclic compounds. The synthesis of Thiazolidine-2,4-diones has been described using a variety of methods. Antidiabetic activity has been discovered in several Thiazolidine-2,4-dione derivatives, which enhance further research. The use of Thiazolidine-2,4-diones to treat antidiabetics has piqued researchers' interest in learning more about thiazolidine-2,4-diones.
Collapse
Affiliation(s)
- Pushkar Kumar Ray
- Department of Pharmacy, Harlal Institute of Management and Technology (HIMT), Plot no-8, Knowledge Park-1, Greater Noida, Uttar Pradesh, 201310, India
| | - Km Shabana
- Department of Pharmacy, Harlal Institute of Management and Technology (HIMT), Plot no-8, Knowledge Park-1, Greater Noida, Uttar Pradesh, 201310, India
| | - Salahuddin
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201306, India
| | - Rajnish Kumar
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, 201306, India
| |
Collapse
|
4
|
Agrawal N, Dhakrey P, Pathak S. A comprehensive review on the research progress of PTP1B inhibitors as antidiabetics. Chem Biol Drug Des 2023; 102:921-938. [PMID: 37232059 DOI: 10.1111/cbdd.14275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 04/17/2023] [Accepted: 05/17/2023] [Indexed: 05/27/2023]
Abstract
Diabetes mellitus (DM) is a serious global health concern affecting over 500 million people. To put it simply, it is one of the most dangerous metabolic illnesses. Insulin resistance is the root cause of 90% of all instances of diabetes, all of which are classified as Type 2 DM. Untreated, it poses a hazard to civilization since it can lead to terrifying consequences and even death. Oral hypoglycemic medicines presently available act in a variety of ways, targeting various organs and pathways. The use of protein tyrosine phosphatase 1B (PTP1B) inhibitors, on the contrary, is a novel and effective method of controlling type 2 diabetes. PTP1B is a negative insulin signaling pathway regulator; hence, inhibiting PTP1B increases insulin sensitivity, glucose absorption, and energy expenditure. PTP1B inhibitors also restore leptin signaling and are considered a potential obesity target. In this review, we have compiled a summary of the most recent advances in synthetic PTP1B inhibitors from 2015 to 2022 which have scope to be developed as clinical antidiabetic drugs.
Collapse
Affiliation(s)
- Neetu Agrawal
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
| | - Parth Dhakrey
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
| | - Shilpi Pathak
- Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, India
| |
Collapse
|
5
|
Discovery of Novel Thiazolidinedione-Derivatives with Multi-Modal Antidiabetic Activities In Vitro and In Silico. Int J Mol Sci 2023; 24:ijms24033024. [PMID: 36769344 PMCID: PMC9917550 DOI: 10.3390/ijms24033024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 01/28/2023] [Accepted: 02/01/2023] [Indexed: 02/08/2023] Open
Abstract
Diabetes mellitus (DM) and related complications continue to exert a significant burden on health care systems globally. Although conventional pharmacological therapies are beneficial in the management of this metabolic condition, it is still necessary to seek novel potential molecules for its management. On this basis, we have synthesised and evaluated the anti-diabetic properties of four novel thiazolidinedione (TZD)-derivatives. The TZD derivatives were synthesised through the pharmacophore hybridisation strategy based on N-arylpyrrole and TZD. The resultant derivatives at different concentrations were screened against key enzymes of glucose metabolism and glucose utilisation in the liver (HEP-G2) cell line. Additionally, peroxisome proliferator-activated receptor-γ activation was performed through docking studies. Docking of these molecules against PPAR-γ predicted strong binding, similar to that of rosiglitazone. Hence, TZDD2 was able to increase glucose uptake in the liver cells as compared to the control. The enzymatic inhibition assays showed a relative inhibition activity; with all four derivatives exhibiting ≥ 50% inhibition activity in the α-amylase inhibition assay and a concentration dependent activity in the α-glucosidase inhibition assay. All four derivatives exhibited ≥30% inhibition in the aldose reductase inhibition assay, except TZDD1 at 10 µg/mL. Interestingly, TZDD3 showed a decreasing inhibition activity. In the dipeptidyl peptidase-4 inhibition assay, TZDD2 and TZDD4 exhibited ≥20% inhibition activity.
Collapse
|
6
|
Impact of Molecular Symmetry/Asymmetry on Insulin-Sensitizing Treatments for Type 2 Diabetes. Symmetry (Basel) 2022. [DOI: 10.3390/sym14061240] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Although the advantages and disadvantages of asymmetrical thiazolidinediones as insulin-sensitizers have been well-studied, the relevance of symmetry and asymmetry for thiazolidinediones and biguanides has scarcely been explored. Regarding symmetrical molecules, only one thiazolidinedione and no biguanides have been evaluated and proposed as an antihyperglycemic agent for treating type 2 diabetes. Since molecular structure defines physicochemical, pharmacological, and toxicological properties, it is important to gain greater insights into poorly investigated patterns. For example, compounds with intrinsic antioxidant properties commonly have low toxicity. Additionally, the molecular symmetry and asymmetry of ligands are each associated with affinity for certain types of receptors. An advantageous response obtained in one therapeutic application may imply a poor or even adverse effect in another. Within the context of general patterns, each compound must be assessed individually. The current review aimed to summarize the available evidence for the advantages and disadvantages of utilizing symmetrical and asymmetrical thiazolidinediones and biguanides as insulin sensitizers in patients with type 2 diabetes. Other applications of these same compounds are also examined as well as the various uses of additional symmetrical molecules. More research is needed to exploit the potential of symmetrical molecules as insulin sensitizers.
Collapse
|
7
|
Recent Updates on Development of Protein-Tyrosine Phosphatase 1B Inhibitors for Treatment of Diabetes, Obesity and Related Disorders. Bioorg Chem 2022; 121:105626. [DOI: 10.1016/j.bioorg.2022.105626] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/19/2021] [Accepted: 01/13/2022] [Indexed: 01/30/2023]
|
8
|
Shouman MA, El-Shazly AH, Elkady MF, Nabil Sabry M, Kamogawa R, Nonaka K, Sasaki M, Kawahara A. A hepatic sinusoids-based microtube reactor for (Z)-5-(4-hydroxybenzylidene)thiazolidine-2,4-dione intermediate drug synthesis. Chem Eng Sci 2022. [DOI: 10.1016/j.ces.2021.116940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Kumar A, Salahuddin, Kumar R, Sahu R, Mishra S, Singh C, Tiglani D. Anti-Diabetic Potentials of Thiazolidinedione Analogues with Efficient
Synthetic Procedures: A Review of Literature. MINI-REV ORG CHEM 2022. [DOI: 10.2174/1570193x18666210224153849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background::
Diabetes mellitus refers to one of the leading cause of diseases that affect large
populations of human and is characterized by a high glucose level in the blood (also known as hyperglycemia).
Thiazolidinedione (TZD) is a five-member heterocyclic compound consisting of three carbons,
nitrogen and sulfur. It is also known as glitazones, can be used as potent hypoglycemic agents
and is also reduce many other cardiovascular risk factors including percutaneous coronary intervention,
carotid and coronary atherosclerosis. As it plays a very important role in the field of medicinal chemistry
or pharmaceutical sciences, novel medicine developed and many are on underdevelopment, these
derivatives have thiazolidinedione as their primary nucleus.
Objective::
This article has discussed the different synthetic procedures of thiazolidinediones that exhibited
potential antidiabetic activity by the activation of PPAR-γ, by reducing the blood glucose levels
and by different metabolic process incorporation.
Conclusion::
Thiazolidinediones has effective profile as the future investigational drug and can be processed
in drug discovery because of its efficient anti-diabetic potential.
Collapse
Affiliation(s)
- Ajay Kumar
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Salahuddin
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Rajnish Kumar
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Rakesh Sahu
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Shivali Mishra
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Chanchal Singh
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| | - Devleena Tiglani
- Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. – 201306,India
| |
Collapse
|
10
|
Sava A, Buron F, Routier S, Panainte A, Bibire N, Constantin SM, Lupașcu FG, Focșa AV, Profire L. Design, Synthesis, In Silico and In Vitro Studies for New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3,4-oxadiazole-2-thiol Scaffold. Int J Mol Sci 2021; 22:7079. [PMID: 34209248 PMCID: PMC8267937 DOI: 10.3390/ijms22137079] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 06/25/2021] [Accepted: 06/25/2021] [Indexed: 12/15/2022] Open
Abstract
Starting from indomethacin (IND), one of the most prescribed non-steroidal anti-inflammatory drugs (NSAIDs), new nitric oxide-releasing indomethacin derivatives with 1,3,4-oxadiazole-2-thiol scaffold (NO-IND-OXDs, 8a-p) have been developed as a safer and more efficient multitarget therapeutic strategy. The successful synthesis of designed compounds (intermediaries and finals) was proved by complete spectroscopic analyses. In order to study the in silico interaction of NO-IND-OXDs with cyclooxygenase isoenzymes, a molecular docking study, using AutoDock 4.2.6 software, was performed. Moreover, their biological characterization, based on in vitro assays, in terms of thermal denaturation of serum proteins, antioxidant effects and the NO releasing capacity, was also performed. Based on docking results, 8k, 8l and 8m proved to be the best interaction for the COX-2 (cyclooxygense-2) target site, with an improved docking score compared with celecoxib. Referring to the thermal denaturation of serum proteins and antioxidant effects, all the tested compounds were more active than IND and aspirin, used as references. In addition, the compounds 8c, 8h, 8i, 8m, 8n and 8o showed increased capacity to release NO, which means they are safer in terms of gastrointestinal side effects.
Collapse
Affiliation(s)
- Alexandru Sava
- Department of Analytical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (A.S.); (A.P.); (N.B.)
- Institut de Chimie Organique et Analytique ICOA, CNRS UMR 7311, Université d’Orléans, 45067 Orléans, France;
| | - Frederic Buron
- Institut de Chimie Organique et Analytique ICOA, CNRS UMR 7311, Université d’Orléans, 45067 Orléans, France;
| | - Sylvain Routier
- Institut de Chimie Organique et Analytique ICOA, CNRS UMR 7311, Université d’Orléans, 45067 Orléans, France;
| | - Alina Panainte
- Department of Analytical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (A.S.); (A.P.); (N.B.)
| | - Nela Bibire
- Department of Analytical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (A.S.); (A.P.); (N.B.)
| | - Sandra Mădălina Constantin
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (S.M.C.); (F.G.L.); (A.V.F.)
| | - Florentina Geanina Lupașcu
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (S.M.C.); (F.G.L.); (A.V.F.)
| | - Alin Viorel Focșa
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (S.M.C.); (F.G.L.); (A.V.F.)
| | - Lenuţa Profire
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy of Iași, 16 University Street, 700115 Iasi, Romania; (S.M.C.); (F.G.L.); (A.V.F.)
| |
Collapse
|
11
|
Petrou A, Fesatidou M, Geronikaki A. Thiazole Ring-A Biologically Active Scaffold. Molecules 2021; 26:3166. [PMID: 34070661 PMCID: PMC8198555 DOI: 10.3390/molecules26113166] [Citation(s) in RCA: 67] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 05/15/2021] [Accepted: 05/20/2021] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND Thiazole is a good pharmacophore nucleus due to its various pharmaceutical applications. Its derivatives have a wide range of biological activities such as antioxidant, analgesic, and antimicrobial including antibacterial, antifungal, antimalarial, anticancer, antiallergic, antihypertensive, anti-inflammatory, and antipsychotic. Indeed, the thiazole scaffold is contained in more than 18 FDA-approved drugs as well as in numerous experimental drugs. OBJECTIVE To summarize recent literature on the biological activities of thiazole ring-containing compounds Methods: A literature survey regarding the topics from the year 2015 up to now was carried out. Older publications were not included, since they were previously analyzed in available peer reviews. RESULTS Nearly 124 research articles were found, critically analyzed, and arranged regarding the synthesis and biological activities of thiazoles derivatives in the last 5 years.
Collapse
Affiliation(s)
| | | | - Athina Geronikaki
- School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; (A.P.); (M.F.)
| |
Collapse
|
12
|
Angelova VT, Pencheva T, Buyukliev R, Yovkova EK, Valkova I, Momekov G, Vulcheva V. Antimycobacterial Activity, In Silico ADME Evaluation, and Docking Study of Novel Thiazolidinedione and Imidazolidinone Conjugates. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2021. [DOI: 10.1134/s1068162021010027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
13
|
Domínguez-Mendoza EA, Galván-Ciprés Y, Martínez-Miranda J, Miranda-González C, Colín-Lozano B, Hernández-Núñez E, Hernández-Bolio GI, Palomino-Hernández O, Navarrete-Vazquez G. Design, Synthesis, and In Silico Multitarget Pharmacological Simulations of Acid Bioisosteres with a Validated In Vivo Antihyperglycemic Effect. Molecules 2021; 26:799. [PMID: 33557136 PMCID: PMC7913794 DOI: 10.3390/molecules26040799] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 01/31/2021] [Accepted: 02/02/2021] [Indexed: 01/16/2023] Open
Abstract
Substituted phenylacetic (1-3), phenylpropanoic (4-6), and benzylidenethiazolidine-2,4-dione (7-9) derivatives were designed according to a multitarget unified pharmacophore pattern that has shown robust antidiabetic activity. This bioactivity is due to the simultaneous polypharmacological stimulation of receptors PPARα, PPARγ, and GPR40 and the enzyme inhibition of aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP-1B). The nine compounds share the same four pharmacophore elements: an acid moiety, an aromatic ring, a bulky hydrophobic group, and a flexible linker between the latter two elements. Addition and substitution reactions were performed to obtain molecules at moderated yields. In silico pharmacological consensus analysis (PHACA) was conducted to determine their possible modes of action, protein affinities, toxicological activities, and drug-like properties. The results were combined with in vivo assays to evaluate the ability of these compounds to decrease glucose levels in diabetic mice at a 100 mg/kg single dose. Compounds 6 (a phenylpropanoic acid derivative) and 9 (a benzylidenethiazolidine-2,4-dione derivative) ameliorated the hyperglycemic peak in a statically significant manner in a mouse model of type 2 diabetes. Finally, molecular dynamics simulations were executed on the top performing compounds to shed light on their mechanism of action. The simulations showed the flexible nature of the binding pocket of AR, and showed that both compounds remained bound during the simulation time, although not sharing the same binding mode. In conclusion, we designed nine acid bioisosteres with robust in vivo antihyperglycemic activity that were predicted to have favorable pharmacokinetic and toxicological profiles. Together, these findings provide evidence that supports the molecular design we employed, where the unified pharmacophores possess a strong antidiabetic action due to their multitarget activation.
Collapse
Affiliation(s)
- Elix Alberto Domínguez-Mendoza
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| | - Yelzyn Galván-Ciprés
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| | - Josué Martínez-Miranda
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| | - Cristian Miranda-González
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| | - Blanca Colín-Lozano
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| | - Emanuel Hernández-Núñez
- Cátedra CONACyT, Departamento de Recursos del Mar, Centro de Investigación y de Estudios Avanzados, IPN, Unidad Mérida, Yucatan 97310, Mexico; (E.H.-N.); (G.I.H.-B.)
| | - Gloria I. Hernández-Bolio
- Cátedra CONACyT, Departamento de Recursos del Mar, Centro de Investigación y de Estudios Avanzados, IPN, Unidad Mérida, Yucatan 97310, Mexico; (E.H.-N.); (G.I.H.-B.)
| | - Oscar Palomino-Hernández
- Computational Biomedicine (IAS-5/INM-9), Forschungszentrum Juelich, 52425 Julich, Germany;
- Department of Chemistry, Rheinisch-Westfälische Technische Hochschule Aachen, 52425 Aachen, Germany
| | - Gabriel Navarrete-Vazquez
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico; (E.A.D.-M.); (Y.G.-C.); (J.M.-M.); (C.M.-G.); (B.C.-L.)
| |
Collapse
|
14
|
Ottanà R, Paoli P, Cappiello M, Nguyen TN, Adornato I, Del Corso A, Genovese M, Nesi I, Moschini R, Naß A, Wolber G, Maccari R. In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications-A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B. Molecules 2021; 26:molecules26020330. [PMID: 33435264 PMCID: PMC7828111 DOI: 10.3390/molecules26020330] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/05/2021] [Accepted: 01/07/2021] [Indexed: 12/31/2022] Open
Abstract
Diabetes mellitus (DM) is a complex disease which currently affects more than 460 million people and is one of the leading cause of death worldwide. Its development implies numerous metabolic dysfunctions and the onset of hyperglycaemia-induced chronic complications. Multiple ligands can be rationally designed for the treatment of multifactorial diseases, such as DM, with the precise aim of simultaneously controlling multiple pathogenic mechanisms related to the disease and providing a more effective and safer therapeutic treatment compared to combinations of selective drugs. Starting from our previous findings that highlighted the possibility to target both aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands (DMLs). Out of the tested compounds, 4f exhibited well-balanced AR/PTP1B inhibitory effects at low micromolar concentrations, along with interesting insulin-sensitizing activity in murine C2C12 cell cultures. The SARs here highlighted along with their rationalization by in silico docking experiments into both target enzymes provide further insights into this class of inhibitors for their development as potential DML antidiabetic candidates.
Collapse
Affiliation(s)
- Rosaria Ottanà
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Palatucci, Polo Universitario Annunziata, 98168 Messina, Italy; (R.O.); (I.A.)
| | - Paolo Paoli
- Department of Scienze Biomediche Sperimentali e Cliniche, Sezione di Scienze Biochimiche, University of Firenze, Viale Morgagni 50, 50134 Firenze, Italy; (P.P.); (M.G.); (I.N.)
| | - Mario Cappiello
- Department of Biology, Biochemistry Unit, University of Pisa, Via S. Zeno, 51, 56123 Pisa, Italy; (M.C.); (A.D.C.); (R.M.)
| | - Trung Ngoc Nguyen
- Molecular Design Lab, Institute of Pharmacy, Freie Universität Berlin, Königin-Luisestr. 2 + 4, 14195 Berlin, Germany; (T.N.N.); (A.N.); (G.W.)
| | - Ilenia Adornato
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Palatucci, Polo Universitario Annunziata, 98168 Messina, Italy; (R.O.); (I.A.)
| | - Antonella Del Corso
- Department of Biology, Biochemistry Unit, University of Pisa, Via S. Zeno, 51, 56123 Pisa, Italy; (M.C.); (A.D.C.); (R.M.)
| | - Massimo Genovese
- Department of Scienze Biomediche Sperimentali e Cliniche, Sezione di Scienze Biochimiche, University of Firenze, Viale Morgagni 50, 50134 Firenze, Italy; (P.P.); (M.G.); (I.N.)
| | - Ilaria Nesi
- Department of Scienze Biomediche Sperimentali e Cliniche, Sezione di Scienze Biochimiche, University of Firenze, Viale Morgagni 50, 50134 Firenze, Italy; (P.P.); (M.G.); (I.N.)
| | - Roberta Moschini
- Department of Biology, Biochemistry Unit, University of Pisa, Via S. Zeno, 51, 56123 Pisa, Italy; (M.C.); (A.D.C.); (R.M.)
| | - Alexandra Naß
- Molecular Design Lab, Institute of Pharmacy, Freie Universität Berlin, Königin-Luisestr. 2 + 4, 14195 Berlin, Germany; (T.N.N.); (A.N.); (G.W.)
| | - Gerhard Wolber
- Molecular Design Lab, Institute of Pharmacy, Freie Universität Berlin, Königin-Luisestr. 2 + 4, 14195 Berlin, Germany; (T.N.N.); (A.N.); (G.W.)
| | - Rosanna Maccari
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Palatucci, Polo Universitario Annunziata, 98168 Messina, Italy; (R.O.); (I.A.)
- Correspondence: ; Tel.: +39-090-6766406
| |
Collapse
|
15
|
Molaei Yielzoleh F, Nikoofar K. Magnetized inorganic–bioorganic nanohybrid [nano Fe
3
O
4
‐SiO
2
@Glu‐Cu (II)]: A novel nanostructure for the efficient solvent‐free synthesis of thiazolidin‐2‐imines. Appl Organomet Chem 2021. [DOI: 10.1002/aoc.6043] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
| | - Kobra Nikoofar
- Department of Chemistry, Faculty of Physics & Chemistry Alzahra University Tehran Iran
| |
Collapse
|
16
|
Thiazole-based and thiazolidine-based protein tyrosine phosphatase 1B inhibitors as potential anti-diabetes agents. Med Chem Res 2020. [DOI: 10.1007/s00044-020-02668-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
17
|
Sánchez-Recillas A, Navarrete-Vázquez G, Hidalgo-Figueroa S, Bonilla-Hernández M, Ortiz-Andrade R, Ibarra-Barajas M, Yáñez-Pérez V, Sánchez-Salgado JC. Pharmacological characterization of the cardiovascular effect of Nibethione: ex vivo, in vivo and in silico studies. J Pharm Pharmacol 2020; 72:1186-1198. [PMID: 32500554 DOI: 10.1111/jphp.13295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 04/16/2020] [Accepted: 04/25/2020] [Indexed: 11/27/2022]
Abstract
OBJECTIVE This work describes the vasorelaxant and antihypertensive effects and the mechanism of action on vascular smooth muscle cells of Nibethione, a synthetic thiazolidinedione derivative. Additionally, evidence of its cytotoxicity is assessed. METHODS Nibethione (NB) was synthesized, and its vasorelaxant effect and mechanism of action were assessed through ex vivo experiments. Molecular docking studies were used to predict the mode of interaction with L-type Ca2+ channel, and in vivo antihypertensive activity was assayed on spontaneously hypertensive rats (SHR). The cytotoxicity potential was evaluated in porcine aortic endothelial cells (PAECs) from primary explants. KEY FINDINGS Nibethione vasorelaxant effect was efficient on KCl (80 mm) and NE-contraction. This effect was deleteriously modified in the presence of potassium channel block drugs, while the maximal contraction induced with NE was significantly decreased by NB; the CaCl2 -induced contraction was abolished entirely. In vivo experiments showed that NB decreased diastolic blood pressure in 20.3 % after its administration on SHR. The molecular docking showed that NB blocks L-type Ca2+ channel, and in vitro tests showed that NB did not produce cytotoxic activity on PAECs (IC50 >1000 µm). CONCLUSIONS Nibethione showed in vivo antihypertensive and ex vivo vasorelaxant effects with implication of voltage-dependent L-type Ca2+ channel blocking, and this may contribute to the research of novel antihypertensive drugs.
Collapse
Affiliation(s)
- Amanda Sánchez-Recillas
- Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Mérida, México
| | - Gabriel Navarrete-Vázquez
- Laboratorio de Química Farmacéutica, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, México
| | - Sergio Hidalgo-Figueroa
- CONACyT, IPICYT/Consorcio de Investigación, Innovación y Desarrollo para las Zonas Áridas, San Luis Potosí, México
| | | | - Rolffy Ortiz-Andrade
- Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Mérida, México
| | - Maximiliano Ibarra-Barajas
- Unidad de Investigación en Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Autónoma de México, Tlalnepantla de Baz, México
| | - Víctor Yáñez-Pérez
- Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán, Mérida, México
| | | |
Collapse
|
18
|
Patel AD, Pasha TY, Lunagariya P, Shah U, Bhambharoliya T, Tripathi RKP. A Library of Thiazolidin-4-one Derivatives as Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors: An Attempt To Discover Novel Antidiabetic Agents. ChemMedChem 2020; 15:1229-1242. [PMID: 32390300 DOI: 10.1002/cmdc.202000055] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2020] [Revised: 04/28/2020] [Indexed: 01/18/2023]
Abstract
Protein tyrosine phosphatase 1B (PTP1B) is an important target for the treatment of diabetes. A series of thiazolidin-4-one derivatives 8-22 was designed, synthesized and investigated as PTP1B inhibitors. The new molecules inhibited PTP1B with IC50 values in the micromolar range. 5-(Furan-2-ylmethylene)-2-(4-nitrophenylimino)thiazolidin-4-one (17) exhibited potency with a competitive type of enzyme inhibition. structure-activity relationship studies revealed various structural facets important for the potency of these analogues. The findings revealed a requirement for a nitro group-including hydrophobic heteroaryl ring for PTP1B inhibition. Molecular docking studies afforded good correlation with experimental results. H-bonding and π-π interactions were responsible for optimal binding and effective stabilization of virtual protein-ligand complexes. Furthermore, in-silico pharmacokinetic properties of test compounds predicted their drug-like characteristics for potential oral use as antidiabetic agents.Additionally, a binding site model demonstrating crucial pharmacophoric characteristics influencing potency and binding affinity of inhibitors has been proposed, which can be employed in the design of future potential PTP1B inhibitors.
Collapse
Affiliation(s)
- Ashish D Patel
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Anand, 388421, India.,Department of Pharmaceutical Chemistry Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India
| | - Thopallada Y Pasha
- Shri Adichunchanagiri College of Pharmacy, Adichunchanagiri University, B G Nagara, Karnataka, 571448, India
| | - Paras Lunagariya
- Smt. R. D. Gardi B. Pharmacy College, Rajkot, Gujarat, 360110, India
| | - Umang Shah
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Anand, 388421, India
| | - Tushar Bhambharoliya
- Wilson College of Textiles, North Carolina State University, North Carolina, 27606, USA
| | - Rati K P Tripathi
- Department of Pharmaceutical Science Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar, Assam, 788011, India.,Department of Pharmaceutical Chemistry Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, 391760, India
| |
Collapse
|
19
|
Vanadium and insulin: Partners in metabolic regulation. J Inorg Biochem 2020; 208:111094. [PMID: 32438270 DOI: 10.1016/j.jinorgbio.2020.111094] [Citation(s) in RCA: 49] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Revised: 04/18/2020] [Accepted: 04/21/2020] [Indexed: 12/12/2022]
Abstract
Since the 1970s, the biological role of vanadium compounds has been discussed as insulin-mimetic or insulin-enhancer agents. The action of vanadium compounds has been investigated to determine how they influence the insulin signaling pathway. Khan and coworkers proposed key proteins for the insulin pathway study, introducing the concept "critical nodes". In this review, we also considered critical kinases and phosphatases that participate in this pathway, which will permit a better comprehension of a critical node, where vanadium can act: a) insulin receptor, insulin receptor substrates, and protein tyrosine phosphatases; b) phosphatidylinositol 3'-kinase, 3-phosphoinositide-dependent protein kinase and mammalian target of rapamycin complex, protein kinase B, and phosphatase and tensin homolog; and c) insulin receptor substrates and mitogen-activated protein kinases, each node having specific negative modulators. Additionally, leptin signaling was considered because together with insulin, it modulates glucose and lipid homeostasis. Even in recent literature, the possibility of vanadium acting against metabolic diseases or cancer is confirmed although the mechanisms of action are not well understood because these critical nodes have not been systematically investigated. Through this review, we establish that vanadium compounds mainly act as phosphatase inhibitors and hypothesize on their capacity to affect kinases, which are critical to other hormones that also act on common parts of the insulin pathway.
Collapse
|
20
|
Bansal G, Thanikachalam PV, Maurya RK, Chawla P, Ramamurthy S. An overview on medicinal perspective of thiazolidine-2,4-dione: A remarkable scaffold in the treatment of type 2 diabetes. J Adv Res 2020; 23:163-205. [PMID: 32154036 PMCID: PMC7052407 DOI: 10.1016/j.jare.2020.01.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 01/07/2020] [Accepted: 01/18/2020] [Indexed: 12/26/2022] Open
Abstract
TZDs, an important pharmacophore in the treatment of diabetes. Various analog-based synthetic strategies and biological significance are discussed. Clinical studies using TZDs along with other antidiabetic agents are also highlighted. SAR has been discussed to suggest the interactions between derivatives and receptor sites. Pyrazole, chromone, and acid-based TZDs can be considered as potential lead molecules.
Diabetes or diabetes mellitus is a complex or polygenic disorder, which is characterized by increased levels of glucose (hyperglycemia) and deficiency in insulin secretion or resistance to insulin over an elongated period in the liver and peripheral tissues. Thiazolidine-2,4-dione (TZD) is a privileged scaffold and an outstanding heterocyclic moiety in the field of drug discovery, which provides various opportunities in exploring this moiety as an antidiabetic agent. In the past few years, various novel synthetic approaches had been undertaken to synthesize different derivatives to explore them as more potent antidiabetic agents with devoid of side effects (i.e., edema, weight gain, and bladder cancer) of clinically used TZD (pioglitazone and rosiglitazone). In this review, an effort has been made to summarize the up to date research work of various synthetic strategies for TZD derivatives as well as their biological significance and clinical studies of TZDs in combination with other category as antidiabetic agents. This review also highlights the structure-activity relationships and the molecular docking studies to convey the interaction of various synthesized novel derivatives with its receptor site.
Collapse
Key Words
- ADDP, 1,1′-(Azodicarbonyl)dipiperidine
- AF, activation factor
- ALP, alkaline phosphatase
- ALT, alanine transaminase
- AST, aspartate transaminase
- Boc, Butyloxycarbonyl
- DBD, DNA-binding domain
- DCM, dichloromethane
- DM, diabetes mellitus
- DMF, dimethylformamide
- DMSO, dimethyl sulfoxide
- DNA, deoxyribonucleic acid
- Diabetes
- E, Entgegen
- ECG, electrocardiogram
- FDA, food and drug administration
- FFA, free fatty acid
- GAL4, Galactose transporter type
- GLUT4, glucose transporter type 4
- GPT, glutamic pyruvic transaminase
- HCl, Hydrochloric Acid
- HDL, high-density lipoprotein
- HEK, human embryonic kidney
- HEp-2, Human epithelial type 2
- HFD, high-fat diet
- IDF, international diabetes federation
- IL-β, interlukin-beta
- INS-1, insulin-secreting cells
- K2CO3, Potassium carbonate
- KOH, potassium hydroxide
- LBD, ligand-binding domain
- LDL, low-density lipoprotein
- MDA, malondialdehyde
- NA, nicotinamide
- NBS, N-bromosuccinimide
- NFκB, nuclear factor kappa-B
- NO, nitric oxide
- NaH, Sodium Hydride
- OGTT, oral glucose tolerance test
- PDB, protein data bank
- PPAR, peroxisome-proliferator activated receptor
- PPAR-γ
- PPRE, peroxisome proliferator response element
- PTP1B, protein-tyrosine phosphatase 1B
- Pd, Palladium
- Pioglitazone
- QSAR, quantitative structure-activity relationship
- RXR, retinoid X receptor
- Rosiglitazone
- SAR, structure-activity relationship
- STZ, streptozotocin
- T2DM, type 2 diabetes mellitus
- TFA, trifluoroacetic acid
- TFAA, trifluoroacetic anhydride
- TG, triglycerides
- THF, tetrahydrofuran
- TNF-α, tumor necrosis factor-alpha
- TZD, thiazolidine-2,4-dione
- Thiazolidine-2,4-diones
- WAT, white adipose tissue
- Z, Zusammen
- i.m, Intramuscular
- mCPBA, meta-chloroperoxybenzoic acid
Collapse
Affiliation(s)
- Garima Bansal
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Moga, Punjab 142001, India
| | - Punniyakoti Veeraveedu Thanikachalam
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Moga, Punjab 142001, India.,GRT Institute of Pharmaceutical Education and Research, GRT Mahalakshmi Nagar, Tiruttani, India
| | - Rahul K Maurya
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Moga, Punjab 142001, India.,Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, India
| | - Pooja Chawla
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Ghal Kalan, Moga, Punjab 142001, India
| | - Srinivasan Ramamurthy
- College of Pharmacy and Health Sciences, University of Science and Technology of Fujairah, United Arab Emirates
| |
Collapse
|
21
|
Design, Synthesis, Antihyperglycemic Studies, and Docking Simulations of Benzimidazole-Thiazolidinedione Hybrids. J CHEM-NY 2019. [DOI: 10.1155/2019/1650145] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
A simple and cheap three-step procedure for the synthesis of three (5Z)-5-[3(4)-(1H-benzimidazol-2-ylmethoxy)benzylidene]-1,3-thiazolidine-2,4-diones has been described via a SN2 reaction of generally recognized as safe hydroxybenzaldehydes and 2-(chloromethyl)-1H-benzimidazole, followed by a Knoevenagel condensation with thiazolidine-2,4-dione in moderated yields. All the newly synthesized compounds were characterized using analytical and spectral studies. In vitro treatment on adipocytes with compounds increased the mRNA expression of two proteins recognized as strategic targets in diabetes: PPARγ and GLUT-4. In silico studies were conducted in order to explain the interaction binding mode of the synthesized compounds on PPARγ. In vivo studies confirmed that compounds 1–3 have robust antihyperglycemic action linked to insulin sensitization mechanisms. The present study provides three compounds with a promising antidiabetic action.
Collapse
|
22
|
Varshney K, Gupta AK, Rawat A, Srivastava R, Mishra A, Saxena M, Srivastava AK, Jain S, Saxena AK. Synthesis,
SAR
and docking studies of substituted aryl phenylthiazolyl phenylcarboxamide as potential protein tyrosine phosphatase 1B (
PTP
1B) inhibitors. Chem Biol Drug Des 2019; 94:1378-1389. [DOI: 10.1111/cbdd.13515] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2018] [Revised: 02/24/2019] [Accepted: 03/03/2019] [Indexed: 01/03/2023]
Affiliation(s)
- Kanika Varshney
- Medicinal and Process Chemistry Division Central Drug Research Institute Lucknow India
- Department of Chemistry Lucknow University Lucknow India
| | - Amit K. Gupta
- Department of Integrative Biology and Pharmacology McGovern Medical School University of Texas Health Science Center at Houston Houston Texas
| | - Arun Rawat
- Biochemistry Division Central Drug Research Institute Lucknow India
| | - Rohit Srivastava
- Biochemistry Division Central Drug Research Institute Lucknow India
| | - Akansha Mishra
- Biochemistry Division Central Drug Research Institute Lucknow India
| | | | | | - Sudha Jain
- Department of Chemistry Lucknow University Lucknow India
| | - Anil K. Saxena
- Medicinal and Process Chemistry Division Central Drug Research Institute Lucknow India
| |
Collapse
|
23
|
Herrera-Rueda MÁ, Tlahuext H, Paoli P, Giacoman-Martínez A, Almanza-Pérez JC, Pérez-Sánchez H, Gutiérrez-Hernández A, Chávez-Silva F, Dominguez-Mendoza EA, Estrada-Soto S, Navarrete-Vazquez G. Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds. Biomed Pharmacother 2018; 108:670-678. [PMID: 30245467 DOI: 10.1016/j.biopha.2018.09.074] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 09/12/2018] [Accepted: 09/12/2018] [Indexed: 11/16/2022] Open
Abstract
In this study, we synthesized five N-Boc-L-tyrosine-based analogues to glitazars. The in vitro effects of compounds 1-5 on protein tyrosine phosphatase 1B (PTP-1B), peroxisome proliferator-activated receptor alpha and gamma (PPARα/γ), glucose transporter type-4 (GLUT-4) and fatty acid transport protein-1 (FATP-1) activation are reported in this paper. Compounds 1 and 3 were the most active in the in vitro PTP-1B inhibition assay, showing IC50s of approximately 44 μM. Treatment of adipocytes with compound 1 increased the mRNA expression of PPARγ and GLUT-4 by 8- and 3-fold, respectively. Moreover, both compounds (1 and 3) also increased the relative mRNA expression of PPARα (by 8-fold) and FATP-1 (by 15-fold). Molecular docking studies were performed in order to elucidate the polypharmacological binding mode of the most active compounds on these targets. Finally, a murine model of hyperglycemia was used to evaluate the in vivo effectiveness of compounds 1 and 3. We found that both compounds are orally active using an exploratory dose of 100 mg/kg, decreasing the blood glucose concentration in an oral glucose tolerance test and a non-insulin-dependent diabetes mellitus murine model. In conclusion, we demonstrated that both molecules showed strong in vitro and in vivo effects and can be considered polypharmacological antidiabetic candidates.
Collapse
Affiliation(s)
| | - Hugo Tlahuext
- Centro de Investigaciones Químicas, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, 62209, Mexico
| | - Paolo Paoli
- Dipartimento di Scienze Biomediche Sperimentali e Cliniche, Sezione di Scienze Biochimiche, Università degli Studi di Firenze, Viale Morgagni 50, 50134, Firenze, Italy
| | - Abraham Giacoman-Martínez
- Laboratorio de Farmacologia, Depto. Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, México, D.F. 09340, Mexico
| | - Julio César Almanza-Pérez
- Laboratorio de Farmacologia, Depto. Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, México, D.F. 09340, Mexico
| | - Horacio Pérez-Sánchez
- Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Engineering Department, Universidad Católica de Murcia (UCAM), E30107, Murcia, Spain
| | | | - Fabiola Chávez-Silva
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico
| | | | - Samuel Estrada-Soto
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico
| | - Gabriel Navarrete-Vazquez
- Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos 62209, Mexico.
| |
Collapse
|